Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Buy" by Analysts

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $62.56.

Several equities analysts have recently commented on the company. Wedbush reiterated an "outperform" rating and set a $70.00 price objective on shares of Protagonist Therapeutics in a research report on Friday, March 28th. The Goldman Sachs Group reduced their price target on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a research report on Monday, February 24th. StockNews.com lowered shares of Protagonist Therapeutics from a "buy" rating to a "hold" rating in a report on Tuesday, December 10th. Truist Financial increased their target price on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a report on Tuesday, March 11th. Finally, HC Wainwright reissued a "buy" rating and issued a $54.00 price target on shares of Protagonist Therapeutics in a research note on Monday, March 10th.

Remove Ads

Protagonist Therapeutics Stock Down 4.4 %

Shares of PTGX stock traded down $2.06 during trading on Monday, hitting $44.44. The company had a trading volume of 1,749,567 shares, compared to its average volume of 808,676. Protagonist Therapeutics has a 52 week low of $24.22 and a 52 week high of $60.60. The stock has a market capitalization of $2.73 billion, a price-to-earnings ratio of 16.71 and a beta of 2.30. The stock's 50-day moving average is $43.48 and its two-hundred day moving average is $42.94.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings data on Friday, February 21st. The company reported $1.98 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $2.07. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The firm had revenue of $170.64 million for the quarter, compared to analysts' expectations of $56.65 million. On average, research analysts predict that Protagonist Therapeutics will post 2.43 EPS for the current fiscal year.

Insider Transactions at Protagonist Therapeutics

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 30,514 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the transaction, the insider now directly owns 83,892 shares of the company's stock, valued at approximately $4,676,140.08. The trade was a 26.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William D. Waddill sold 4,000 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the completion of the transaction, the director now owns 13,130 shares of the company's stock, valued at $712,302.50. This trade represents a 23.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 64,776 shares of company stock worth $3,585,010. Company insiders own 5.40% of the company's stock.

Hedge Funds Weigh In On Protagonist Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of Montreal Can boosted its position in Protagonist Therapeutics by 4.5% during the 4th quarter. Bank of Montreal Can now owns 6,250 shares of the company's stock valued at $241,000 after acquiring an additional 270 shares in the last quarter. Maryland State Retirement & Pension System boosted its position in shares of Protagonist Therapeutics by 1.4% during the fourth quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company's stock valued at $779,000 after purchasing an additional 278 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in Protagonist Therapeutics by 10.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock worth $121,000 after purchasing an additional 295 shares during the period. Louisiana State Employees Retirement System grew its stake in Protagonist Therapeutics by 1.1% in the fourth quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company's stock worth $1,112,000 after purchasing an additional 300 shares during the period. Finally, KBC Group NV raised its holdings in Protagonist Therapeutics by 54.4% in the fourth quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after purchasing an additional 737 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.